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Amoxicillin, an antibiotic that is widely prescribed for various infections, is associated with a very low rate of drug-induced liver 
injury; hepatitis and cholestasis are rare complications. Here we present a case of a 39-year-old woman who was diagnosed with 
abdominal actinomycosis and received amoxicillin treatment. The patient displayed hepatocellular and bile-duct injury, in 
addition to elevated levels of liver enzymes. The patient was diagnosed with amoxicillin-induced cholestatic hepatitis. When 
amoxicillin was discontinued, the patient’s symptoms improved and her liver enzyme levels reduced to near to the normal range. 
(Korean J Hepatol 2011;17:229-232)
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INTRODUCTION
Amoxicillin is a rare cause of drug-induced liver injury.
1-3 
Clinical course of hepatocellular injury by amoxicillin is usually 
benign. The abnormalities resolve within a few months 
following discontinuation of amoxicillin treatment. 
A retrospective study from the United Kingdom estimated that 
liver injury from amoxicillin occurs in approximately 0.3 cases 
per 10,000 treated patients.
4,5 When identified early and treated 
appropriately, the prognosis is excellent. However, because of its 
low occurrence, amoxicillin-induced liver injury has sometimes 
been overlooked. In such cases, severe injury and even death 
have been reported due to progressive liver failure and hepatic 
bile duct injury.
6
We report a case of a 39-year-old woman who developed 
cholestatic hepatitis with bile duct damage and hepatocellular 
injury following amoxicillin treatment for abdominal actinomycosis.
CASE REPORT
A 39-year-old woman with no significant clinical history was 
admitted to the hospital with a distended abdomen and weight 
loss. The physical examination revealed abdominal distension, 
abdominal tenderness, and rebound tenderness affecting the 
entire abdomen. The hemoglobin level was 7.3 g/dL (12-16 g/dL); 
white blood cell count, 12,440/mm
3 (4,000-1,000/mm
3), with 
67.4% neutrophils and 7.3% lymphocytes; and platelet count, 
605,000/mm
3 (150,000-450,000/mm
3). Laboratory data showed 
total bilirubin 0.3 mg/dL (0.2-1.2 mg/dL), aspartate aminotransferase 
(AST) 17 IU/L (10-40 IU/L), alanine aminotransferase (ALT) 12 
IU/L (5-40 IU/L), alkaline phosphatase (ALP) 127 IU/L (35-123 
IU/L), and C-reactive protein 11.22 mg/dL (0.5 mg/dL ). The 
erythrocyte sedimentation rate was 46 mm/h (0-10 mm/h); the 
prothrombin time was 17.4 s (9.2-13.4 s), with an INR of 1.53 
(0.83-1.2); and the total protein level was 6.5 g/dL (6-8.2 g/dL). 230  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
Table 1. Council for International Organizations of Medical 
Sciences (CIOMS) and Clinical Diagnostic Scale (CDS) scores 
of the patient
CIOMS
  1. Time to onset +2 (60 days)
  2. Course of reaction +1 (≤30 days)
  3. Risk factor for drug reaction 0 (None)
  4. Concomitant drugs 0 (None)
  5. Nondrug-related causes +2 (Rule out)
  6. Previous information on drug +2 (Reaction labeled)
  7. Response of readministration  0 (Not available)
  Total Score +7
CDS 
  1. Temporal relationship
        a. Time to onset +1 (60 days)
        b. Time to withdrawal +3 (4 days)
        c .  T i m e  t o  n o r m a l i z e 0( 8  m o n t h s )
  2. Nondrug-related causes +3 (Complete exclusion)
  3. Extrahepatic manifestatins  +2 (Pruritis, cytopenia)
  4. Response to readministration  0 (Absent re-challenge)
  5. Previous information on drug +2 (Yes)
  Total Score  +11
CIOMS, Council for International Organization of Medical Sciences; 
CDS, Clinical Diagnostic Scale.
Air fluid levels and an obstructive ileus were evident by plain 
abdominal X-ray. Abdominopelvic computed tomography con-
firmed a mass surrounded by an abscess in the ascending colon. 
The patient was referred to the Department of Surgery, and a 
right hemi-colectomy was performed. The pathology showed 
findings consistent with actinomycotic abscesses containing 
sulfur granules, and the patient was diagnosed with abdominal 
actinomycosis. One month later, the patient was discharged from 
the hospital with oral amoxicillin (2 g per day), and follow-up 
was planned in the outpatient clinic.
Eight weeks after discharge, the patient returned to the 
hospital with nausea and abdominal discomfort. The laboratory 
findings were: AST, 77 IU/L; ALT, 157 IU/L; and ALP, 100 
IU/L. A follow-up visit was planned. The patient was re-admitted 
to the hospital 14 weeks later, with general weakness, abdominal 
discomfort, and nausea. However, there were no symptoms 
associated with idiosyncratic reactions, such as pruritus, arthralgia, 
urticaria. Laboratory tests showed increased levels of total 
bilirubin 2.9 mg/dL, AST 371 IU/L, ALT 245 IU/L, and ALP 184 
IU/L. On admission, the patient had a blood pressure of 120/70 
mmHg, a body temperature of 36.7℃, and a pulse rate of 74/min. 
Mild right upper quadrant tenderness was present, with no signs 
of hepatomegaly or splenomegaly, upon physical examination.
A complete blood count revealed the following: hemoglobin, 
11.4 g/dL; white blood cell count, 3,360/mm
3; and platelet count, 
51,000/mm
3. The serum total bilirubin, AST, ALT, and ALP 
were 2.0 mg/dL, 192 IU/L, 216 IU/L, and 199 IU/L, respectively. 
The levels of viral hepatitis markers (HBsAg, HBsAb, HBcAb, 
HAV IgM/IgG, HCV Ab), autoimmune markers (ANA, anti-LKM, 
AMA, anti-SLA, IgG) were all within normal ranges, and other 
viral markers were; CMV IgG,, positive; CMV IgM, negative; 
EBV IgG, positive; EBV IgM, negative; HSV IgG, positive; 
HSV IgM, negative, suggesting no evidence of viral or auto-
immune hepatitis The patient displayed a Council for Inter-
national Organization of Medical Sciences (CIOMS) score were: 
time to onset, 60 days (+2); course of reaction, within 30 days (+1); 
non drug-related causes, rule out (+2); previous information on 
drug, reaction labeled in the product characteristics (+2), making 
a total of 7 and a Clinical Diagnostic Scale (CDS) score were: 
time to onset, 60 days (+1); time to withdrawal, 4 days (+3); 
non drug-related causes, complete exclusion (+3); extrahepatic 
manifestations, pruritis and cytopenia (+2); previous information 
on drug, yes (+2), making a total of 11, indicating probable and 
possible liver damage (Table 1). A liver biopsy was performed, 
and the pathology showed cholestasis, hepatocellular inflammation, 
and bile duct damage and loss (nearly 50% in 11/24 portal tracts) 
(Fig. 1). The patient was diagnosed with cholestatic hepatitis 
associated with amoxicillin. After discontinuation of amoxicillin, 
we prescribed Ursodeoxycholic acid 600 mg per day (10 mg/kg) 
to her. The patient was discharged from the hospital with 
improved symptoms and laboratory findings. The patient was 
followed for 14 weeks after discontinuation of the amoxicillin, 
and all symptoms resolved. The final laboratory findings in the 
outpatient clinic were: total bilirubin, 2.3 mg/dL; AST, 108 IU/L; 
ALT, 79 IU/L; and ALP, 163 IU/L (Fig. 2). 
DISCUSSION
Drug-induced hepatitis is a common cause of liver injury and 
acute liver failure, particularly in patients treated with antibiotics.
7,8 
Amoxicillin causes liver injury in 0.3 of 10,000 prescriptions. 
However, when prescribed in combination with clavulanate, 
the incidence of amoxicillin-induced liver injury increases to 1.7 
in 10,000 prescriptions.
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Figure 1. Pathology of liver biopsy. (A) Portal inflammation with 
bile-duct injury. Note the presence of vacuolar degeneration (arrowhead) 
and necrosis (arrows) of the bile duct epithelial cells (H&E, ×400).
(B) Portal tract displaying the absence of the bile duct (H&E, ×400).
(C) Hepatic lobule showing mildly fatty changes and cholestasis 
(H&E, ×400).
Figure 2. Changes in liver enzyme levels. After discontinuation 
of amoxicillin, the levels of aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphate (ALP), and 
bilirubin gradually improved.
amoxicillin/clavulanate hepatotoxicity is unknown. However, 
the clavulinic acid of amoxicillin/clavulanate combination 
therapy has been implicated as the cause of hepatotoxicity, as 
re-challenge with amoxicillin alone is typically well tolerated 
compared with amoxicillin/clavulanate.
5 Furthermore, clavulanic 
acid combined with other β-lactams can also lead to liver injury.
9 
Thus, liver injury with these therapies is most likely an idiosy-
ncratic reaction to amoxicillin.
Amoxicillin is an oral semi-synthetic penicillin with a broader 
spectrum of activity than other penicillins. Amoxicillin distributes 
to the liver, lungs, gallbladder, and prostate, where it can mildly 
elevate liver enzyme levels and produce jaundice and abnormalities 
of bile secretion. Liver injury is a rare side effect of amoxicillin 
treatment.
10,11 Pathology evaluation is helpful for the diagnosis 
of drug-induced liver injury. Severe cases of amoxicillin-induced 
liver injury, some resulting in death, have been associated 
with progressive liver failure and the vanishing bile duct 
syndrome.
12,13 
In 1996, García Rodríquez et al
5 performed a retrospective 
study of 422,646 individuals to assess liver injury in patients 
treated with amoxicillin compared with patients treated with 
amoxicillin/clavulanate in the United Kingdom. Of these 
individuals, 62,313 received amoxicillin/clavulanate, and 329,213 
A B
C
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received amoxicillin alone. Thirty-five individuals presented 
with acute liver injury: 14 of these cases (0.003%) were among 
users of amoxicillin alone, and 21 cases (0.017%) were among 
the users of amoxicillin/clavulanate. Salvo et al
14 analyzed a 
database of the Italian Inter-regional Group of Pharmacovigilance 
during 2007 to determine the side effects associated with 
amoxicillin and amoxicillin/clavulanate. Amoxicillin/clavulanate- 
related adverse drug reactions had occurred in 1088 cases; with 
amoxicillin alone, there were 1095 cases. The percentage of 
hepatobiliary injury was higher for amoxicillin/clavulanate than 
for amoxicillin alone. Serious liver injury related to amoxicillin 
occurred in four cases, which included two with cholestatic 
hepatitis, one with hepatitis, and one with hepatic necrosis. 
In the present case, the patient had no significant medical 
history and was not receiving any other drug except amoxicillin; 
there were no significant abnormalities on laboratory testing. 
There are no specific guidelines for the clinical evaluation to 
diagnose drug-induced liver injury, but the scales often used for 
causality include the CIOMS and CDS. In the present case, these 
scales indicated “probable” and “possible” liver injury, in support 
of the diagnosis. In addition, the findings of hepatocellular 
injury, cholestasis, and the loss of bile duct were identified on 
liver biopsy. Consequentially, the patient was diagnosed with 
cholestatic hepatitis associated with amoxicillin. The symptoms 
and laboratory findings improved after the amoxicillin was 
discontinued. 
Compared with the amoxicillin/clavulanate regimen, treatment 
with amoxicillin alone as a cause for liver injury is rare. In 
addition, diagnosing drug-induced liver injury is problematic 
because of its vague symptoms and lack of definite diagnostic 
guidelines. Amoxicillin is well known as a safe drug even when 
administered to patients with chronic liver disease or cirrhosis.
15 
Therefore, amoxicillin-induced liver injury may not be suspected 
at an early stage, as in the present case. However, when liver 
injury occurs, hepatocellular liver injury is common.
5 In the case 
reported here, liver biopsy and laboratory findings showed 
significant bile duct injury and cholestatic hepatitis. The 
vanishing bile duct syndrome has been reported as a cause of 
death in a patient with amoxicillin-induced liver injury.
6 For 
most cases of drug-induced hepatotoxicity, the prognosis is good 
when the drug is discontinued. Nevertheless, it is important to 
consider that liver failure and death can occur with inappropriate 
patient management. Thus, patients receiving amoxicillin should 
be closely monitored for signs of bile duct injury or cholestatic 
hepatitis resulting from amoxicillin-induced liver injury.
Several current and newly developed drugs can lead to liver 
injury, but studies investigating drug hepatotoxicity are rare. In 
the majority of cases, the prognosis is good when administration 
of the drug is discontinued. However, the administration of 
well-tolerated drugs such as amoxicillin can lead to liver failure 
and death in rare cases. Physicians should continue to monitor 
the potential hepatotoxicity of drugs, even drugs with a very low 
prevalence of liver toxicity.
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